Full text is available at the source.
Abstract
Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) in patients with cardiovascular disease, overweight or obesity, and no diabetes.
- Semaglutide is associated with a decrease in the occurrence of cardiovascular complications.
- The trial focused on individuals who have cardiovascular disease but do not have diabetes.
- Participants in the study were categorized as having either overweight or obesity.
Simplified